Wed, November 27, 2024
Tue, November 26, 2024
Mon, November 25, 2024
Sun, November 24, 2024
Thu, November 14, 2024
Tue, November 12, 2024
Wed, October 23, 2024
Thu, April 23, 2009
Mon, February 2, 2009
[ Mon, Feb 02nd 2009 ]: Nathan Burkes
Is Obama a rock star?
Fri, January 30, 2009

Exelixis Announces April 7th Webcast of Presentation at the Leerink Swann Cancer Roundtable Conference

  Copy link into your clipboard //health-fitness.news-articles.net/content/2011/ .. -leerink-swann-cancer-roundtable-conference.html
  Print publication without navigation Published in Health and Fitness on by Market Wire
          🞛 This publication is a summary or evaluation of another publication

SOUTH SAN FRANCISCO, Calif.--([ BUSINESS WIRE ])--Exelixis, Inc. (Nasdaq:EXEL) announced that Gisela Schwab, M.D., the companya™s executive vice president and chief medical officer, will present at the Leerink Swann Cancer Roundtable Conference at 1:55 p.m. EDT / 10:55 a.m. PDT on Thursday, April 7, 2011, in New York. During the presentation, Dr. Schwab will review the most recent publicly available data for cabozantinib in castration-resistant prostate cancer (CRPC), discuss the pivotal trial plans and regulatory strategy for the compound in CRPC and provide a general business update.

The presentation will be webcast and may be accessed in the Event Calendar under Investors at [ www.exelixis.com ].

About Exelixis

Exelixis, Inc. is a biotechnology company committed to developing small molecule therapeutics for the treatment of cancer. Exelixis is focusing its resources and development efforts exclusively on cabozantinib, its most advanced solely-owned product candidate, in order to maximize the therapeutic and commercial potential of this compound. Exelixis believes cabozantinib has the potential to be a high-quality, differentiated pharmaceutical product that can make a meaningful difference in the lives of patients. Exelixis has also established a portfolio of other novel compounds that it believes have the potential to address serious unmet medical needs. For more information, please visit the companya™s web site at [ www.exelixis.com ].